Why AstraZeneca and others racing to make a COVID-19 vaccine should be more open about the process
- Written by Duncan Matthews, Professor of Intellectual Property Law, Queen Mary University of London
The dangers of poor disclosure. Mongkolchon AkesinAstraZeneca is resuming clinical trials for the COVID-19 vaccine, ChAdOx1 nCoV-19, following confirmation that is safe to do so. The trials were paused when one of the participants developed an “unexplained illness”.
The pause is over, but the concerns that it raises about transparency...